TQC2938 not checked
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.”In the company’s words, NCT06789289 on ClinicalTrials.gov
- Tested for
- Chronic Obstructive Pulmonary Disease
- Main trialPhase 2
- “The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It is anticipated that 256 subjects will be enrolled.”In the company’s words, NCT06789289 on ClinicalTrials.gov
Other drugs for Chronic Obstructive Pulmonary Disease
- TQC3721Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- EnsifentrineMerck & Co. · Nuance Pharma · Phase 3
- HSK39004Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- AstegolimabRoche · Phase 3
- Alpha-1 MPGrifols Therapeutics LLC · Phase 3
- JKN2401Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3
Coming up1
- 17 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 17 Mar 2027 | A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | |
| Phase 2Completed | 12 Sep 2025 | Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis | |
| Phase 1Unknown | Nov 2024 | A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026